Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Mostly consistent with the label regarding gradual tapering and risks after abrupt/rapid discontinuation. Several details (e.g., seizure control worsening, specific guidance attributed to Mayo Clinic, urgent care thresholds, and agitation/confusion) are not supported by the provided label excerpts.
Category Scores
Accurate Statements
When discontinuing LYRICA, taper gradually over a minimum of 1 week.
2.1 Important Administration Instructions: “When discontinuing LYRICA, taper gradually over a minimum of 1 week [see Warnings and Precautions (5.6)].”; 5.6 “Withdraw LYRICA gradually… If discontinued, taper gradually over a minimum of 1 week.”
LYRICA can cause symptoms after abrupt or rapid discontinuation.
5.6 Increased Risk of Adverse Reactions with Abrupt or Rapid Discontinuation: “Following abrupt or rapid discontinuation… symptoms including insomnia, nausea, headache, anxiety, hyperhidrosis, and diarrhea.”
The taper schedule should be set by the clinician/prescriber based on the patient’s situation.
2.1/5.6 indicate tapering should occur (gradually, minimum of 1 week) and that discontinuation should be managed; no specific schedule is provided in the excerpts, but the general requirement for gradual tapering aligns with clinician-directed tapering.
Unsupported Statements
Withdrawal symptoms can include a return or worsening of the condition being treated (such as nerve pain or seizures).
The provided label excerpt for abrupt/rapid discontinuation lists insomnia, nausea, headache, anxiety, hyperhidrosis, and diarrhea, but does not mention return/worsening of treated condition or seizures.
Stopping pregabalin abruptly can lead to withdrawal symptoms.
The label supports adverse reactions with abrupt or rapid discontinuation (5.6), but the label excerpts use specific symptom examples and do not explicitly use the term “withdrawal symptoms” or link to “withdrawal-type symptoms” phrasing.
Mayo Clinic advises tapering pregabalin under medical guidance rather than stopping at once.
The labeling excerpts do not contain or cite Mayo Clinic recommendations.
Mayo Clinic advises that patients should not stop Lyrica suddenly.
The labeling excerpts do not contain or cite Mayo Clinic recommendations.
Rebound symptoms and withdrawal risk depend on how abruptly the dosing changed.
5.6 supports increased risk after abrupt or rapid discontinuation, but the provided excerpt does not explicitly state dependence on “how abruptly” beyond “abrupt or rapid discontinuation,” nor does it mention “rebound symptoms.”
Urgent care is recommended if stopping or tapering leads to severe symptoms, including significant worsening seizure control (if used for seizures).
The provided label excerpt does not mention worsening seizure control, and it does not provide an “urgent care” threshold or instruction.
Urgent care is recommended if stopping or tapering leads to severe agitation or confusion.
The provided label excerpt for 5.6 does not mention agitation or confusion, and it does not provide guidance to seek “urgent care” for these symptoms.
Contradictions
Important Omissions
Specific label-listed symptoms of abrupt/rapid discontinuation (insomnia, nausea, headache, anxiety, hyperhidrosis, diarrhea).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response correctly emphasizes gradual tapering and the existence of symptoms after abrupt/rapid discontinuation. However, it adds unsupported elements (worsening seizure control, agitation/confusion, and urgent care advice) and does not include the label’s specific example symptoms, which could lead to incomplete recognition of label-consistent discontinuation reactions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Includes multiple statements not supported by the provided label excerpts (Mayo Clinic attribution, condition-specific rebound/worsening including seizures, agitation/confusion, and urgent care thresholds).
Suggested Improvement
Remove or qualify non-label-supported claims; align directly to label language in 5.6 (gradual taper over minimum of 1 week and the listed symptom examples) and avoid adding urgent-care instructions or specific seizure/agitation outcomes unless present in the labeling excerpts provided.